Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma

BJU International

Volumn 118, Issue 3, 2016, Pages 408-415

  Seront, Emmanuel ^a,b   Rottey, Sylvie ^c   Filleul, Bertrand ^b   Glorieux, Philippe ^d   Goeminne, Jean Charles ^e   Verschaeve, Vincent ^f   Vandenbulcke, Jean Marie ^g   Sautois, Brieuc ^h   Boegner, Petra ⁱ   Gillain, Aline ^a   van Maanen, Aline ^a   Machiels, Jean Pascal ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b Centre Hospitalier Jolimont Lobbes   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d Clinique du Sud Luxembourg   (Belgium)

^e Department of Medical Oncology   (Belgium)

^f Grand Hopital de Charleroi   (Belgium)

^g Réseau Hospitalier de Médecine Sociale ^*  (Belgium)

^h UNIVERSITY OF LIÈGE   (Belgium)

ⁱ Centre Hospitalier Epicura   (Belgium)

Author keywords

BEZ235; mTOR inhibitor; PI3K inhibitor; transitional cell carcinoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DACTOLISIB; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM COMPLEX; PROTEIN KINASE B;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; FEMALE; FEVER; GASTRITIS; GENE; GENE MUTATION; HEARTBURN; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY FAILURE; LIVER TOXICITY; MALAISE; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PIK3CA GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PRURITUS; RASH; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84982084226     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.13415     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90
2. von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602–8
3. Albers P, Park SI, Niegisch G et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol 2011; 22: 288–94
4. Bellmunt J, Theodore C, Demkov T et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27: 4454–61
5. Dreicer R, Li H, Cooney MM, Wilding G, Roth BJ, Eastern Cooperative Oncology G. Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group. Cancer 2008; 112: 2671–5
6. Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 2007; 25: 265–70
7. Ko YJ, Canil CM, Mukherjee SD et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol 2013; 14: 769–76
8. Lorusso V, Pollera CF, Antimi M et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on bladder cancer. Eur J Cancer 1998; 34: 1208–12
9. McCaffrey JA, Hilton S, Mazumdar M et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997; 15: 1853–7
10. Papamichael D, Gallagher CJ, Oliver RT, Johnson PW, Waxman J. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Brit J Cancer 1997; 75: 606–7
11. Pronzato P, Vigani A, Pensa F, Vanoli M, Tani F, Vaira F. Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. Am J Clin Oncol 1997; 20: 519–21
12. Vaughn DJ, Srinivas S, Stadler WM et al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer 2009; 115: 4110–7
13. Witte RS, Manola J, Burch PA, Kuzel T, Weinshel EL, Loehrer PJ Sr. Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial. Invest New Drugs 1998; 16: 191–5
14. Apolo AB, Parnes HL, Madan RA, Gulley JL, Wright JJ, Hoffman JH. A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC). J Clin Oncol 2014; 32
15. Bellmunt J, Gonzalez-Larriba JL, Prior C et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol 2011; 22: 2646–53
16. Daugaard GSL, Agerbaek M, Sternberg CN, Van Herpen C, Collette S. Phase I results from a study of lapatinib with gemcitabine and cisplatin (GC) in advanced/metastatic bladder cancer. J Clin Oncol 2013; 31: 31
17. Dreicer R, Li H, Stein M et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 2009; 115: 4090–5
18. Gallagher DJ, Milowsky MI, Gerst SR et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 2010; 28: 1373–9
19. Gerullis H, Eimer C, Ecke TH et al. A phase II trial of temsirolimus in second-line metastatic urothelial cancer. Med Oncol 2012; 29: 2870–6
20. Hussain MH, MacVicar GR, Petrylak DP et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007; 25: 2218–24
21. Necchi A, Mariani L, Zaffaroni N et al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol 2012; 13: 810–6
22. Twardowski P, Stadler WM, Frankel P et al. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology 2010; 76: 923–6
23. Wong YN, Litwin S, Vaughn D et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol 2012; 30: 3545–51
24. Wulfing C, Machiels JP, Richel DJ et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009; 115: 2881–90
25. O'Reilly KE, Rojo F, She QB et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500–8
26. Sun SY, Rosenberg LM, Wang X et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65: 7052–8
27. Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014; 507: 315–22
28. Aveyard JS, Skilleter A, Habuchi T, Knowles MA. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 1999; 80: 904–8
29. Knowles MA, Platt FM, Ross RL, Hurst CD. Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev 2009; 28: 305–16
30. Meric-Bernstam F, Akcakanat A, Chen H et al. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res 2012; 18: 1777–89
31. Neshat MS, Mellinghoff IK, Tran C et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98: 10314–9
32. Seront E, Rottey S, Sautois B et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol 2012; 23: 2663–70
33. Seront E, Pinto A, Bouzin C, Bertrand L, Machiels JP, Feron O. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation. Brit J Cancer 2013; 109: 1586–92
34. Maira SM, Stauffer F, Brueggen J et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7: 1851–63
35. Sangale Z, Prass C, Carlson A et al. A robust immunohistochemical assay for detecting PTEN expression in human tumors. Appl Immunohistochem Mol Morphol 2011; 19: 173–83
36. Bellmunt J, Choueiri TK, Fougeray R et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010; 28: 1850–5
37. Bendell JC, Kurkjian C, Infante JR et al. A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors. Invest New Drugs 2015; 33: 463–71
38. Moon du G, Lee SE, Oh MM et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells. Int J Oncol 2014; 45: 1027–35
39. Gil-martin M, Fumoleau P, Isambert N et al. A dose-finding phase Ib study of BEZ235 in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer. Cancer Res 2014; 73: P2-16-22